Novo, GlaxoSmithKline and Merck-backed molecular profiling platform HTG offered almost 3.6 million shares priced at $14 each.

Pet medicine developer Jaguar Animal Health, backed by Napo Pharmaceuticals, raised $20m after receiving $2.2m of venture funding.

Galapagos has increased the target for its upcoming IPO on Nasdaq to $230m, while $55m of the stock could be bought by AbbVie and Johnson & Johnson.

The wearable fitness device maker has raised $83m in funding from investors including SoftBank and Qualcomm.

Novo-backed CoLucid Pharmaceuticals secured $55m in the offering, and will use the proceeds to advance its migraine treatment through clinical trials.

The health services management company, founded by UPMC Health Plan and The Advisory Board Company, has targeted $100m for its initial public offering.

The cancer therapeutics developer, backed by Novo and Immunocore, raised the cash less than a year after closing a nine-figure series A round.

The newly formed pharmaceutical company, backed by investors including Novo, also raised $40m to advance its lead product through clinical trials.

Shareholder Johnson & Johnson bought stock in the molecular diagnostics technology provider as it floated in Brussels at a valuation of more than $500m.